Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based ¹⁷⁷Lu-DOTATATE treatment of NET patients.

ABSTRACT:

Purpose

Radionuclide therapy with ¹⁷⁷Lu-DOTATATE is well established for patients with advanced somatostatin receptor-positive neuroendocrine tumors with a standard schedule of 7.4 GBq at four occasions. However, this approach does not consider individual variability affecting the tumor radiation dose or dose to organs at risk. Therefore, it is important to assess more personalized strategies. The aim of this phase II trial was to evaluate individualized ¹⁷⁷Lu-DOTATATE for which the number of cycles varied based on renal dosimetry.

Methods

Patients were eligible if they had a progressive, somatostatin receptor-positive neuroendocrine tumor with a Ki 67 labeling index < 20%. They received cycles of 7.4 GBq of ¹⁷⁷Lu-DOTATATE at 10 ± 2-week inte

SUBMITTER: Sundlov A 

PROVIDER: S-EPMC9399027 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature